Stock listing
A4ZZ0Z Stock Price, News, Filings & Events — Q32 Bio Inc.
Selected listing: A4ZZ0Z · LS · EUR · DE
This page tracks Q32 Bio Inc.'s A4ZZ0Z:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A4ZZ0Z:LS. A4ZZ0Z:LS is the stock-level entry point for investors researching Q32 Bio Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A4ZZ0Z:LS
- Asset type
- Stock
- Market cap
- $330.4M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Q32 Bio Inc. A4ZZ0Z:LS stock context
This page tracks Q32 Bio Inc.'s A4ZZ0Z:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A4ZZ0Z:LS. A4ZZ0Z:LS is the stock-level entry point for investors researching Q32 Bio Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Q32 Bio Inc.
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
September 14, 2026
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
July 14, 2026
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
July 13, 2026
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
July 13, 2026
Research Q32 Bio Inc.
Q32 Bio Inc. investor report
Review AI stock analysis and investor report context for A4ZZ0Z:LS.
Q32 Bio Inc. company profile
View the public company page for Q32 Bio Inc. on 6ix.
Q32 Bio Inc. news
Read company news and market updates connected to Q32 Bio Inc..
Q32 Bio Inc. investor events
Find investor webinars, events, and replay context for Q32 Bio Inc..
Alternate listings
QTTB:NASDAQ
US · USD
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.
DB0:GETTEX
DE · EUR
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.
0T6G:LSE
GB · USD
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.
QTTB:BOATS
US · USD
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.
DB0:DUS
DE · EUR
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.
DB0:FWB
DE · EUR
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.
DB0:MUN
DE · EUR
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.
DB0:SWB
DE · EUR
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.
DB0:TRADEGATE
DE · EUR
Alternate listing for Q32 Bio Inc.; the primary context on this page is A4ZZ0Z:LS.